Asparaginase市場：現狀分析與預測（2022-2028）

Asparaginase Market: Current Analysis and Forecast (2022-2028)

出版日期: 2023年07月31日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於製藥行業研發的擴大以及 FDA 對Asparaginase藥物的批准增加，Asparaginase市場預計將穩定增長約 16.4%。根據美國食品藥品監督管理局（FDA）報告的數據，2021年6月30日，FDA批准了Asparaginase新劑型Erwinia chrysanthemi（重組）-rywn（Rylaze）。 Rylaze 被批准作為兒童和成人治療策略的一部分，用於治療類似於 ALL 的侵襲性血癌。此外，2022 年 11 月，Jazz Pharmaceutical PLC 宣布 Ryleyse FDA-Seq（Asparaginase Erwinia 宣布美國 FDA 批准用於肌內（IM）施用 chrysanthemi（重組）-rywn 的補充生物製劑許可申請（SBLA））。因此，製藥行業的擴張、研發的增加以及 FDA 的批准可能會對預測期內的市場增長產生積極影響。

按類型，市場分為大腸桿菌、菊歐文氏菌和聚乙二醇化產品。在2021年的市場中，大腸桿菌類別佔據壓倒性份額。這主要是由於癌症治療中對大腸桿菌Asparaginase的需求增加。根據紐約羅徹斯特大學對三種Asparaginase製劑的藥代動力學比較研究，大腸桿菌Asparaginase的出現是由於癌症治療中對大腸桿菌Asparaginase的需求增加。大腸桿菌Asparaginase的生物半衰期（1.44 天）比大腸桿菌（1.44 天）和 PEG Asparaginase的生物半衰期短得多（0.65 天）。因此，大腸桿菌被廣泛用於治療ALL，並且是治療癌症的首選藥物。因此，癌症治療中對大腸桿菌的需求不斷增加預計將在預測期內積極推動Asparaginase市場。

根據應用，市場分為急性淋巴細胞白血病、急性髓細胞白血病和其他（霍奇金病）。急性淋巴細胞白血病領域預計在預測期內將以高複合年增長率增長。這是由於它越來越多地用於治療淋巴增殖性疾病和淋巴瘤。根據健康指標與評估研究所的數據，2019 年全球報告了約 153,000 例急性淋巴細胞白血病新病例。這些是預計在預測期內推動市場的因素。

根據最終用途，市場分為醫院、診所、零售藥店和在線藥店。 2021年，醫院佔據壓倒性的市場份額。由於醫療基礎設施的快速發展，預計預測期內對Asparaginase的需求將增加，研究活動將增加，導致主要市場參與者的研發投資相應增加。例如，2019 年，芝加哥百萬大學獲得了約 100 萬美元的天冬□胺資助，用於開發毒性較小的化療藥物治療 ALL。

為了更好地了解Asparaginase市場的採用情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、歐洲其他地區）、亞太地區（中國、日本、印度等亞太地區）以及世界其他地區。由於 ALL 和 LBL 患病率上升等因素，預計亞太地區在預測期內將以顯著的複合年增長率增長。此外，該地區研發活動的增加預計將積極推動市場增長。例如，在印度，2021年3月，印度理工學院（IIT）印多爾開發了一種新蛋白質，這是一種治療淋巴母細胞淋巴瘤的工程方法，具有急性副作用。

Asparaginase is a drug that is used in the treatment of acute lymphatic leukemia (ALL), lymphoblastic lymphoma (LBL), and certain types of blood cancers. It works by breaking down the amino acid asparagine and may block the growth of the tumour cells that requires asparagine to grow. It is an enzyme obtained chemically from the bacterium Escherichia coli (E.coli), Erwinia chrysanthemi, Pegylated, fungi, algae, and many more. Research and development studies are being carried out for the expansion of its application area in various fields such as nanomedicine, biomedical engineering, and many more.

The Asparaginase Market is expected to grow at a steady rate of around 16.4% owing to the expansion of pharmaceutical industry R&D and an increase in FDA approvals for asparaginase drugs. According to the data from the Food Drug Administration (FDA) report, on June 30, 2021, the FDA approved Erwinia chrysanthemi (recombinant)-rywn (Rylaze) a new form of asparaginase. Rylaze was approved as a part of the treatment regime in children and adults for the treatment of aggressive blood cancer that resembles ALL. Additionally, in November 2022, Jazz Pharmaceutical plc announced the USFDA approval for supplementary biologics license application (SBLA) to the intramuscular (IM) dosing for Rylaze FDA seeking (Asparaginase Erwinia chrysanthemi (recombinant)-rywn, for use as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL in adult and pediatric patients. Thus, with expansion in the pharmaceutical industry, R&D, and increased FDA approvals, there will be a positive impact on market growth during the forecast period.

Based on Type, the market is segmented into Escherichia coli (E.coli), Erwinia chrysanthemi, and Pegylated. E.coli category held the dominant share in the market in 2021. This is mainly due to the increase in demand for E.Coli asparaginase in cancer treatment According to the study on Comparative pharmacokinetic studies of three asparaginase preparations conducted by the University of Rochester, New York. Erwinia chrysanthemi asparaginase has a much shorter biological half-life (0.65 days) than E.coli (1.44 days) or PEG asparaginase. Hence E.coli is widely used in the treatment of ALL and is the preferred drug of choice for the treatment of cancer. Thus the increased demand for E.coli for cancer treatment is anticipated to drive the market for asparaginase positively during the forecast period.

Based on Application, the market is segmented into acute lymphoblastic leukemia, acute myeloid leukemia, and Other (Hodgkin's disease). The acute lymphoblastic leukemia segment is expected to grow with a high CAGR during the forecast period. this is attributed to its increase use in the treatment of lymphoproliferative disorders and lymphoma. According to the Institute of Health Metrics and Evaluation, in 2019 about 153,000 new cases of acute lymphoblastic leukemia were reported globally. These are the elements that are anticipated to fuel the market during the forecast period.

Based on End-use, the market is segmented into hospitals, clinics, retail pharmacy and online pharmacy. Hospitals held the dominant share of the market in 2021. The rapidly growing health infrastructure is expected to increase the demand for asparaginase during the forecasting period, leading to increase research activities, along with this rising investment in research and development by the key market players. For instance, in 2019 University of Millions Chicago, secured funding of about USD 1 million for aspargine for the development of less toxic chemotherapy use in the treatment of ALL.

For a better understanding of the market adoption of asparaginase, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia Pacific is anticipated to grow with a significant CAGR during the forecast period, owing to factors, including the rising prevalence of ALL and LBL across the region. Furthermore, the increase in research and development activity in the region is anticipated to boost market growth positively. For instance, in India, in March 2021, the Indian Institute of Technology (IIT) Indore developed a new protein, an engineering approach, to treat lymphoblastic lymphoma with an acute side effect.

Some of the major players operating in the market include: Jazz Pharmaceuticals plc, Servier Pharmaceutical LLC, medac GmbH, Kyowa Kirin co, ltd., Taj Pharmaceuticals Limited., Creative Enzymes.,Bio Vendor R&D, Gennova Biopharmaceuticals Limited., Actiza Pharmaceutical Private Limited, Porton Biopharma

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Asparaginase Market
2.2. Research Methodology of the Asparaginase Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ASPARAGINASE MARKET COVID-19 IMPACT

6 GLOBAL ASPARAGINASE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT

7.1. Escherichia coli
7.2. Euinia crysanthemi
7.3. Pegylated

8 MARKET INSIGHT BY APPLICATION

8.1. Acute lymphoblastic leukimia
8.2. Acute myleoblastic leukimia
8.3 Other (Hodgkin's disease)

9 MARKET INSIGHTS BY END-USERS

9.1 Hospitals

Clinics

Retail Pharmacy

Online Pharmacy

10 MARKET INSIGHTS BY REGION

10.1. North America Asparaginase Market
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe Asparaginase Market
- 10.2.1. Germany
- 10.2.2. UK
- 10.2.3 Italy
- 10.2.4. France
- 10.2.8. Rest of Europe

Asia-Pacific Asparaginase Market